LGND - Ligand Pharmaceuticals Incorporated (LGND) Q1 2024 Earnings Call Transcript
2024-05-07 23:03:10 ET
Ligand Pharmaceuticals Incorporated (LGND)
Q1 2024 Earnings Conference Call
May 07, 2024 04:30 PM ET
Company Participants
Michael Jeong - Investor Relations
Todd Davis - Chief Executive Officer
Paul Hadden - Senior Vice President, Investments & Business Development
Karen Reeves - Senior Vice President-Clinical Strategy & Investments
Matt Korenberg - President & Chief Operating Officer
Tavo Espinoza - Chief Financial Officer
Conference Call Participants
Matt Hewitt - Craig-Hallum Capital Group
Joe Pantginis - H.C. Wainwright
Presentation
Operator
Thank you for standing by. Our name is Benjamin and I will be your conference operator today. At this time, I would like to welcome everyone to the Ligand First Quarter 2024 Earnings Webcast. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. [Operator Instructions] Thank you.
I would now like to turn the call over to Michael Jeong, Investor Relations. Please go ahead.
Michael Jeong
Hello, everyone and welcome to our earnings call for the first quarter of 2024. During the call today, we will review the financial results we released after today's market close and offer commentary on our partnered pipeline and business development activity, after which we will host a question-and-answer session. Our earnings release and link to webcast of today's call can be found in the Investor Relations section of our website at ligand.com.
Participating on the call today will be our CEO, Todd Davis; our COO, Matt Korenberg; our CFO, Tavo Espinoza; our Senior VP Investments and Business Development, Paul Hadden; and our Senior VP of Clinical Strategy and Investments, Dr. Karen Reeves. This call is being recorded and the audio portion will be archived in the Investors section of our website.
Today on the call we will make forward-looking statements regarding our financial results and other matters related to the company's business. Please refer to this Safe Harbor statement related to these forward-looking statements which are subject to risks and uncertainties.
We remind you that actual events or results may differ materially from those projected or discussed and that all forward-looking statements are based upon current available information. Ligand assumes no obligation to update these statements. To better understand the risks and uncertainties that could cause actual results differ, we refer you to the documents that Ligand filed with the Securities and Exchange Commission including our most recent Forms 10-Q and 10-K....
Ligand Pharmaceuticals Incorporated (LGND) Q1 2024 Earnings Call Transcript